483 related articles for article (PubMed ID: 28465508)
1. CD8 T cells contribute to lacrimal gland pathology in the nonobese diabetic mouse model of Sjögren syndrome.
Barr JY; Wang X; Meyerholz DK; Lieberman SM
Immunol Cell Biol; 2017 Sep; 95(8):684-694. PubMed ID: 28465508
[TBL] [Abstract][Full Text] [Related]
2. Toll-Like Receptor 7 Is Required for Lacrimal Gland Autoimmunity and Type 1 Diabetes Development in Male Nonobese Diabetic Mice.
Debreceni IL; Chimenti MS; Serreze DV; Geurts AM; Chen YG; Lieberman SM
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322152
[TBL] [Abstract][Full Text] [Related]
3. Reversible lacrimal gland-protective regulatory T-cell dysfunction underlies male-specific autoimmune dacryoadenitis in the non-obese diabetic mouse model of Sjögren syndrome.
Lieberman SM; Kreiger PA; Koretzky GA
Immunology; 2015 Jun; 145(2):232-41. PubMed ID: 25581706
[TBL] [Abstract][Full Text] [Related]
4. Type I Interferon Signaling Is Required for Dacryoadenitis in the Nonobese Diabetic Mouse Model of Sjögren Syndrome.
Chaly Y; Barr JY; Sullivan DA; Thomas HE; Brodnicki TC; Lieberman SM
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347820
[TBL] [Abstract][Full Text] [Related]
5. Salivary-gland-protective regulatory T-cell dysfunction underlies female-specific sialadenitis in the non-obese diabetic mouse model of Sjögren syndrome.
Barr JY; Wang X; Kreiger PA; Lieberman SM
Immunology; 2018 Oct; 155(2):225-237. PubMed ID: 29750331
[TBL] [Abstract][Full Text] [Related]
6. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome.
Johnson BC; Morton JI; Trune DR
Otolaryngol Head Neck Surg; 1992 Apr; 106(4):394-9. PubMed ID: 1565490
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice.
Kong L; Robinson CP; Peck AB; Vela-Roch N; Sakata KM; Dang H; Talal N; Humphreys-Beher MG
Clin Exp Rheumatol; 1998; 16(6):675-81. PubMed ID: 9844759
[TBL] [Abstract][Full Text] [Related]
8. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
[TBL] [Abstract][Full Text] [Related]
9. IL-27 promotes pathogenic T cells in a mouse model of Sjögren's disease.
Debreceni IL; Barr JY; Upton EM; Chen YG; Lieberman SM
Clin Immunol; 2024 Jul; 264():110260. PubMed ID: 38788885
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.
Meng Z; Klinngam W; Edman MC; Hamm-Alvarez SF
PLoS One; 2017; 12(9):e0184781. PubMed ID: 28902875
[TBL] [Abstract][Full Text] [Related]
11. Matriptase deletion initiates a Sjögren's syndrome-like disease in mice.
Yin H; Kosa P; Liu X; Swaim WD; Lai Z; Cabrera-Perez J; Di Pasquale G; Ambudkar IS; Bugge TH; Chiorini JA
PLoS One; 2014; 9(2):e82852. PubMed ID: 24551030
[TBL] [Abstract][Full Text] [Related]
12. Animal models for autoimmune disease-associated xerostomia and xerophthalmia.
Humphreys-Beher MG
Adv Dent Res; 1996 Apr; 10(1):73-5. PubMed ID: 8934930
[TBL] [Abstract][Full Text] [Related]
13. Smad4 in T cells plays a protective role in the development of autoimmune Sjögren's syndrome in the nonobese diabetic mouse.
Kim D; Kim JY; Jun HS
Oncotarget; 2016 Dec; 7(49):80298-80312. PubMed ID: 27880731
[TBL] [Abstract][Full Text] [Related]
14. Early Covert Appearance of Marginal Zone B Cells in Salivary Glands of Sjögren's Syndrome-Susceptible Mice: Initiators of Subsequent Overt Clinical Disease.
Peck AB; Nguyen CQ; Ambrus J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671965
[TBL] [Abstract][Full Text] [Related]
15. Novel animal models for Sjögren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice.
Sharma R; Zheng L; Guo X; Fu SM; Ju ST; Jarjour WN
J Autoimmun; 2006 Dec; 27(4):289-296. PubMed ID: 17207605
[TBL] [Abstract][Full Text] [Related]
16. IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjögren's syndrome.
Brayer JB; Cha S; Nagashima H; Yasunari U; Lindberg A; Diggs S; Martinez J; Goa J; Humphreys-Beher MG; Peck AB
Scand J Immunol; 2001; 54(1-2):133-40. PubMed ID: 11439159
[TBL] [Abstract][Full Text] [Related]
17. Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sjögren's Syndrome: the influence of sex hormones and genetic background.
Czerwinski S; Mostafa S; Rowan VS; Azzarolo AM
Exp Eye Res; 2014 Nov; 128():15-22. PubMed ID: 25218176
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and Sjögren syndrome.
Manganelli P; Fietta P
Semin Arthritis Rheum; 2003 Aug; 33(1):49-65. PubMed ID: 12920696
[TBL] [Abstract][Full Text] [Related]
19. Tissue-Resident Memory CD8+ T Cells Acting as Mediators of Salivary Gland Damage in a Murine Model of Sjögren's Syndrome.
Gao CY; Yao Y; Li L; Yang SH; Chu H; Tsuneyama K; Li XM; Gershwin ME; Lian ZX
Arthritis Rheumatol; 2019 Jan; 71(1):121-132. PubMed ID: 30035379
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
Yin H; Nguyen CQ; Samuni Y; Uede T; Peck AB; Chiorini JA
Arthritis Res Ther; 2012 Feb; 14(1):R40. PubMed ID: 22369699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]